Loading…
Loading…
IMVIQ (IMV Inc.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
IMVIQ does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for IMVIQ and 80,000+ other tickers.
See exactly how IMVIQ's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for IMVIQ and 80,000+ other tickers.
IMV Inc. is a biotechnology firm focused on developing cancer treatments, currently in the clinical trial phase. It leverages its proprietary DPX immune-modulating technology platform to create a range of therapeutic candidates aimed at both solid and blood-related cancers. Its primary investigational therapy, maveropepimut-S, is an immunotherapy built on the DPX platform, designed to target cells that express survivin. This compound is currently undergoing Phase II clinical evaluations for conditions such as diffuse large B-cell lymphoma, ovarian cancer, as well as solid tumors of the…
IMV (OTCMKTS:IMVIQ - Get Free Report) and Whitehawk Therapeutics (NASDAQ: WHWK - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, analyst recommendations, dividends and profitability. Valuation and Earnings This table compares IMV and
Earnings and Valuation This table compares NexImmune and IMV"s top-line revenue, earnings per share and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NexImmune N/A N/A -$32.34 million ($18.29) N/A IMV $330,000.00 0.00 -$37.99 million ($4.59) N/A NexImmune has higher earnings, but lower revenue than IMV. Risk and Volatility NexImmune has